Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000760308 | SCV000890161 | pathogenic | not provided | 2018-07-11 | criteria provided, single submitter | clinical testing | The Q3237X variant in the VPS13B gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The Q3237X variant is not observed in large population cohorts (Lek et al., 2016). We interpret Q3237X as a pathogenic variant. |
Labcorp Genetics |
RCV003768283 | SCV004687310 | pathogenic | Cohen syndrome | 2023-10-14 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln3237*) in the VPS13B gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in VPS13B are known to be pathogenic (PMID: 15141358, 16648375, 20461111). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 620087). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV003768283 | SCV005667408 | likely pathogenic | Cohen syndrome | 2024-01-31 | criteria provided, single submitter | clinical testing |